Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Intravenous delivery of mesenchymal stromal cells reverses Müller cell endoplasmic reticulum stress in diabetic retinopathy

Yan W., Guo R., Liu T., Liu Y., Ping R., Liu B.

Animal Study on Systemic / IV, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41456048
PMCID
PMC12853727
DOI
10.1186/s13287-025-04876-4

Abstract (original English)

Background Mesenchymal stromal cells (MSCs) have emerged as a promising disease-modifying therapy for the complications of diabetes mellitus (DM), including diabetic retinopathy (DR). However, the optimal treatment regimen remains unclear, and challenges persist regarding the timing, route of delivery and the mechanisms underlying the therapeutic effects. This study focused on human umbilical cord-derived mesenchymal stromal cells (hUC-MSCs), to elucidate their retinal protective effects, and investigate the underlying mechanisms by which a single intravenous injection might ameliorate the pathological alterations of DR. Methods Two time points after the development of DM were chosen for the in vivo experiments to study the effects of the intervention after different times of exposure to hyperglycemia. hUC-MSCs were injected via the tail vein at 8 and 16 weeks after STZ injection. Retinal samples were collected 2 weeks post-treatment to analyze the therapeutic effect of MSCs on DR. In vitro experiments were conducted using a Müller cell line and a retinal microvascular endothelial cell line cultured under high-glucose conditions, with treatment by hUC-MSCs conditioned media (MSC-CM), to explore the underlying mechanisms. Results After a single intravenous injection of hUC-MSCs at week 16 and not 8 weeks post-STZ injection, retinal tissue showed improved thickness of the inner n

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
RetinaCell LineMesenchymal Stem CellsUmbilical CordAnimalsHumansRatsRats, Sprague-DawleyDiabetic RetinopathyDiabetes Mellitus, Experimental

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research